Allscripts reported a revenue of $152 million, an increase from $145 million in the third quarter of 2021. The company's operating profit also saw a year-over-year increase of over 30%. Additionally, Allscripts generated $42 million in cash flow from continuing operations.

Allscripts reported second quarter results with year-over-year growth in revenue, gross profit, and Adjusted EBITDA. The company completed the sale of its Hospital and Large Physician Practices Segment. Consolidated GAAP net loss totaled $64 million, while non-GAAP net income was $22 million.

Allscripts reported a strong fourth quarter, with significant year-over-year growth in bookings, operating income, Adjusted EBITDA, and free cash flow. The company's Q4 revenue increased to $392 million from $386 million in Q4 2020. GAAP diluted EPS was $0.68, and non-GAAP diluted EPS was $0.79.

Allscripts announced its Q3 2021 financial results, reporting revenue of $369 million and GAAP diluted EPS of $0.12. The company also generated $57 million of cash flow from continuing operations and $35 million of free cash flow. Allscripts is increasing its 2021 outlook for Adjusted EBITDA and free cash flow.

Allscripts announced positive financial results for Q2 2021, with GAAP diluted EPS at $0.15 and non-GAAP diluted EPS at $0.23, a 35% year-over-year increase. The company generated $69 million in cash flow from continuing operations and $51 million in free cash flow. They are increasing their 2021 outlook for Adjusted EBITDA and free cash flow and affirming revenue expectations.

Allscripts' Q4 2020 results demonstrated continued progress with revenue of $386 million and non-GAAP revenue of $415 million. The company reported a GAAP EPS of $4.82 and a non-GAAP EPS of $0.29, driven by strategic actions and portfolio optimization. The company closed sales of EPSi and CarePort Health, repurchased $280 million of stock, and ended the quarter in a net cash position.

Allscripts announced its Q2 2020 financial results, reporting revenue of $406 million and a GAAP loss per share of $0.05. The company signed a definitive agreement to sell its EPSi business unit for $365 million and focused on improving its cost structure, which led to expanded Adjusted EBITDA margins.

Allscripts reported a 6% year-over-year increase in bookings, reaching $312 million in Q4 2019. GAAP revenue increased to $451 million, while a GAAP net loss of $19 million was reported, contrasting with the previous year's net income. The company also extended its managed services agreement with Northwell Health and saw its contract revenue backlog rise to $4.4 billion.